Cost –Utility of Liraglutide Plus Standard of Care Versus Standard of Care in People with Type 2 Diabetes and Cardiovascular Risk in Thailand

ConclusionCompared to the SoC treatment, adding liraglutide at the current cost is not cost-effective at the local WTP. People with T2D with ASCVD would have the most potential gain from adding liraglutide treatment compared to other populations.

http://link.springer.com/10.1007/s13300-023-01371-y

Source: Diabetes Therapy - January 31, 2023 Category: Endocrinology Source Type: research